Fig. 8

Therapeutic sensitivity in different CCRGPI subgroups. A TIDE, T-cell dysfunction, T-cell exclusion score, and IPS in different CCRGPI subgroups. B Comparison of the CCRGPI between the STS and LTS groups in the GSE212550 dataset. C Kaplan‒Meier survival analysis of different CCRGPI subgroups in the IMvigor210 dataset. D Comparison of the IRGPI, IRGS, and m6Arisk between the STS and LTS groups in the GSE212550 dataset. E Predicted IC50 values of 30 drugs in different CCRGPI subgroups (***p < 0.001, ****p < 0.0001). CCRGPI cancer-associated fibroblast (CAF)-cancer cell crosstalk-related gene prognostic index, IC50 50% inhibitory concentration, IPS immunophenoscore, IRGPI immune-related gene prognostic index, IRGS immune-related gene signature, LTS long-term survivors, m6Arisk m6A-based risk score, STS short-term survivors, TIDE tumor immune dysfunction and exclusion